United States Drug Patent 4,603,146: Claim Scope, Expiration, and Tretinoin Patent Landscape

U.S. Patent No. 4,603,146 protects a method of using topical vitamin A acid, commonly known as tretinoin or all-trans retinoic acid, to treat sun-damaged human skin through a maintenance-therapy regimen. The patent is directed to anti-aging treatment, not to the chemical compound itself, a particular cream formulation, or acne treatment. It issued July 29, 1986, and its ordinary 17-year patent term expired July 29, 2003.[1,2]

The patent therefore has no current exclusionary value in the United States. Its historical importance is greater than its present enforcement value: it helped establish topical tretinoin as a treatment for photoaged skin and represents an early method-of-use patent covering retinoid-based dermatology.

What does U.S. Patent 4,603,146 protect?

The patent protects a topical treatment method with several cumulative limitations:

Claim limitation	Scope
Patient	Human
Disease or condition	Sun-damaged skin
Anatomical site	Epidermis
Active ingredient	Vitamin A acid, generally understood as retinoic acid or tretinoin
Dosage form	Composition in an emollient vehicle
Treatment objective	Retarding and reversing collagen loss, elastic-fiber abnormalities, small-vessel deterioration, and abnormal epithelial growth
Treatment pattern	Maintenance therapy
Dose limitation	A sub-irritating dose
Claimed result	Improved and maintained firmness, turgor, and elasticity

Claim 2 narrows claim 1 to human facial skin.

The patent does not claim tretinoin as a chemical compound. It also does not claim every topical retinoid, every retinoic-acid formulation, or every use of tretinoin. Its protection depends on the combination of the active ingredient, vehicle, treatment setting, skin condition, dose, and therapeutic purpose.

How should claim 1 be construed?

Claim 1 is a method-of-treatment claim rather than a composition claim. Infringement would require practice of substantially all claim limitations. A product manufacturer would generally face risk only if its labeling, promotional materials, instructions, or other evidence showed an intended use matching the claimed treatment method.

Vitamin A acid

“Vitamin A acid” is the historical terminology used for retinoic acid. In the context of this patent, the term is most naturally associated with tretinoin, also called all-trans retinoic acid.

The claim does not expressly recite:

A particular concentration;
A specific cream, gel, lotion, or ointment;
A fixed application frequency;
A defined treatment duration;
A particular brand;
A specific manufacturing process; or
A particular molecular form beyond the claimed vitamin A acid.

The absence of a concentration limitation broadens the chemical-use aspect of the claim, but the “sub-irritating dose” limitation narrows it by requiring a dosage selected to avoid substantial irritation.

Emollient vehicle

The composition must contain an emollient vehicle. This limitation distinguishes the claim from administration of neat active ingredient or a non-emollient delivery system, although the patent claim does not define a precise list of acceptable excipients.

A formulation containing tretinoin in a cream, lotion, or ointment would more readily satisfy this limitation than an aqueous solution or a transdermal system without an emollient function. The legal analysis would depend on the formulation’s actual composition and the meaning of “emollient” in the patent specification and prosecution history.

Sun-damaged human skin

The treatment must be directed to sun-damaged skin. This limitation is important because it separates the claimed use from:

Acne treatment;
Treatment of psoriasis or keratinization disorders;
Treatment of intrinsic aging unrelated to photodamage;
Treatment of nonhuman skin; and
General cosmetic use without a sun-damage indication.

Claim 2 further limits the treatment to human facial skin.

Maintenance therapy

The claim requires a “program of maintenance therapy.” This language indicates an ongoing treatment regimen intended to preserve improvements rather than a one-time application or short induction course.

The patent does not specify a precise maintenance interval. That lack of numerical detail may increase practical coverage across different dosing schedules, but it also makes the claim dependent on the factual characterization of the regimen.

Sub-irritating dose

The dose must be selected to provide a sub-irritating dose of vitamin A acid. This is a functional limitation. It requires that the amount and formulation be sufficiently low, or sufficiently tolerable, to avoid the level of irritation contemplated by the claim.

A formulation that is intentionally prescribed at an irritating dose for a short induction period may fall outside the literal scope of the claim if it is not part of a sub-irritating maintenance regimen. Conversely, a product can present infringement risk even without a specific concentration if evidence shows that it is intended for long-term, low-irritation treatment of photoaged skin.

What does claim 2 add?

Claim 2 is a dependent claim covering human facial skin. It does not materially expand the patent. It narrows the broader human-skin claim to the most commercially relevant treatment site.

The dependent claim may have had evidentiary value during enforcement because facial-skin use is easier to establish through product labeling, clinical studies, advertising, and physician prescribing information. It has no independent commercial blocking effect today because the patent has expired.

What is the patent’s legal status and expiration date?

U.S. Patent No. 4,603,146 issued July 29, 1986.[1] Because it was governed by the pre-Uruguay Round patent-term rule, its ordinary term was 17 years from issuance. On that basis, the patent expired July 29, 2003.

Event	Date
Patent issued	July 29, 1986
Ordinary term	17 years from issuance
Expiration	July 29, 2003
Current enforceability	Expired
Current Paragraph IV significance	None
Current injunction or damages exposure	None for conduct occurring after expiration

Patent-term adjustment and patent-term extension provisions introduced under later statutes generally do not convert this patent into a currently enforceable right. The controlling status should be confirmed through the USPTO patent record and maintenance-fee history, but the patent’s ordinary term has long ended.[2]

What patents protect topical tretinoin and photoaging treatment?

The relevant landscape divides into five patent categories:

Patent category	Typical subject matter	Relevance to U.S. 4,603,146
Active-ingredient patents	Tretinoin or other retinoid compounds	Not covered by the patent
Method-of-use patents	Use of tretinoin for photoaging, acne, pigmentation, or keratinization disorders	Directly adjacent
Formulation patents	Cream, gel, microsphere, encapsulated, or controlled-release formulations	Separate from the patent
Manufacturing patents	Synthesis, purification, polymorph, or particle-size control	Separate from the patent
Regulatory exclusivity	New-drug, pediatric, orphan, or clinical-data exclusivity	Separate from patent rights

U.S. Patent 4,603,146 occupies the second category. It does not create a broad platform right over all tretinoin products. A later patent could have covered a specific formulation, delivery system, particle structure, stability profile, or separate indication without duplicating the expired patent.

What formulation patents are relevant to tretinoin?

Formulation patent risk historically centered on technologies intended to improve tolerability, stability, delivery, or cosmetic acceptability. Relevant claim types include:

Microsphere formulations;
Encapsulated tretinoin;
Controlled-release systems;
Reduced-irritation compositions;
Stabilized retinoic-acid formulations;
Specific oil-in-water cream systems;
Gel formulations with defined solvents or polymers; and
Combinations of tretinoin with moisturizers, antioxidants, or other dermatological agents.

These formulations may have supported branded products even after the basic compound and the 4,603,146 method claim became unpatentable. A formulation patent must be analyzed separately by patent number, claim language, expiration date, terminal disclaimers, and Orange Book listing.

The expired patent does not prevent a company from pursuing a formulation patent for a new and non-obvious vehicle. It also does not immunize a later formulation from infringement of an unexpired formulation or manufacturing patent.

What is the Orange Book status of U.S. Patent 4,603,146?

U.S. Patent 4,603,146 should not be treated as a current Orange Book barrier. Its claims concern a topical method of treating photoaged skin, and its patent term expired in 2003.

The Orange Book may contain current or historical patent information for approved tretinoin products, depending on the product, NDA holder, listed use, and the status of each patent.[3] Orange Book listing is product-specific. It does not establish that every tretinoin product practices a listed patent, and it does not revive an expired patent.

For generic approval purposes, an applicant could encounter:

No patent certification for an expired patent;
A Paragraph III certification for a listed unexpired patent awaiting expiration;
A Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed; or
A Section viii statement carving out a patented method of use from labeling.

Patent 4,603,146 itself cannot support a current Paragraph IV dispute because it is expired.

When did tretinoin lose exclusivity for photoaging treatment?

Tretinoin’s exclusivity developed in stages:

Exclusivity type	Effect
Compound and early product rights	Protected pharmaceutical development and initial commercial products
Acne-use approvals	Supported branded topical tretinoin products
Photoaging method claims	Covered selected anti-photoaging treatment regimens
Formulation patents	Protected particular delivery systems and vehicles
FDA regulatory exclusivity	Applied only for the period assigned to a qualifying approval
Patent 4,603,146	Expired July 29, 2003

The expiration of this patent did not eliminate all possible protection around tretinoin. It removed one method-of-use barrier. Generic manufacturers still had to address any unexpired formulation, manufacturing, or product-specific patent listed for the relevant reference product.

Are there Paragraph IV challenges involving this patent?

No current Paragraph IV challenge can produce an exclusionary effect against a generic based on U.S. Patent 4,603,146 because the patent expired in 2003.

A Paragraph IV certification is relevant only to an unexpired listed patent. Once a patent expires, the applicant does not need to invalidate it or wait for its expiration. Historical ANDA litigation involving topical tretinoin may have involved different patents, products, formulations, or labeling theories.

Does biosimilar risk apply to tretinoin?

No. Tretinoin is a small-molecule drug, not a biologic. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.[4]

The principal regulatory and patent issues are therefore:

Pharmaceutical equivalence;
Bioequivalence or product-specific comparative requirements;
Same dosage form and route;
Labeling carve-outs;
Formulation patents;
Manufacturing patents; and
Orange Book certifications.

What generic launch scenarios exist for topical tretinoin?

Immediate launch after patent clearance

A generic manufacturer can launch after approval if no unexpired patent or regulatory exclusivity blocks marketing. The expired 4,603,146 patent does not prevent this scenario.

Paragraph III timing

If an unexpired patent is listed for the reference product, an ANDA applicant may certify that it will wait until the patent expires. This approach avoids patent litigation but delays launch.

Paragraph IV launch

A Paragraph IV certification can support an earlier launch if the applicant prevails, the patent owner does not sue within the statutory period, or the dispute is resolved through settlement.

Section viii carve-out

If the only protected use is photoaging treatment and the generic label excludes that use, a section viii statement may be available. The feasibility depends on the listed patent, approved labeling, prescribing information, and whether the proposed label still induces the patented use.

Because claim 1 of Patent 4,603,146 is an expired method claim, it cannot independently require a carve-out.

What litigation and settlements affect this patent?

The patent’s age and expiration date eliminate present litigation exposure under its claims. Any historical litigation would now be relevant mainly for:

Claim construction;
Prosecution-history interpretation;
Scope of “sub-irritating dose”;
Meaning of “maintenance therapy”;
The role of promotional materials in induced infringement; and
The distinction between photoaging and acne indications.

No current settlement can extend the expired patent’s exclusionary term. A private agreement could allocate commercial rights or restrict conduct contractually, but it could not create patent infringement liability after expiration.

How strong was the patent estate?

The patent was commercially meaningful when enforceable but structurally narrow compared with a compound or broad formulation patent.

Strength factor	Assessment
Chemical coverage	Weak; no compound claim
Treatment coverage	Targeted to photoaged human skin
Formulation coverage	Limited to an emollient vehicle
Dose coverage	Broad in concentration terms, narrowed by sub-irritating requirement
Regimen coverage	Maintenance therapy required
Facial use	Covered specifically by dependent claim 2
Generic substitution risk	High after expiration
Current blocking power	None
Historical strategic value	High for anti-photoaging positioning

The strongest commercial aspect was the connection between tretinoin and sustained treatment of photoaged skin. The weakest aspect was reliance on functional and contextual limitations rather than ownership of the active ingredient or a defined formulation.

How does this patent compare with formulation and manufacturing patents?

Patent 4,603,146 is a use patent. Its value depended on proving that a product was intended for the claimed use and regimen.

A formulation patent usually presents a different risk profile. It may be infringed by the product’s composition even if the manufacturer avoids photoaging claims. A manufacturing patent may create risk at the API or finished-product supply stage without appearing in the product label.

For freedom-to-operate analysis, the expired patent should therefore be removed from the current blocking set, while unexpired patents should be screened across:

Active pharmaceutical ingredient manufacture;
Particle size and crystal form;
Cream and gel composition;
Encapsulation and controlled release;
Stability and packaging;
Photoaging and acne methods; and
FDA-listed product patents.

What is the commercial impact of expiration?

Expiration shifts competition from patent exclusion to regulatory execution and market economics. Relevant commercial effects include:

Entry by multiple generic tretinoin manufacturers;
Price erosion in common strengths and dosage forms;
Greater substitution by pharmacies and payers;
Continued differentiation through vehicle, tolerability, packaging, and consumer branding;
Reduced value of broad anti-aging claims that lack an enforceable patent; and
Potential residual value in unexpired formulation or device patents.

Revenue exposure depends on the specific branded product and indication. Patent 4,603,146 cannot support post-2003 monopoly revenue. A company relying on this patent alone would have no current U.S. patent protection for topical photoaging treatment.

Key Takeaways

U.S. Patent 4,603,146 covers a method of applying topical vitamin A acid, generally tretinoin, in an emollient vehicle to sun-damaged human skin.
Claim 1 requires maintenance therapy and a sub-irritating dose.
Claim 2 narrows the method to human facial skin.
The patent does not claim tretinoin as a compound or protect every tretinoin formulation.
The patent issued July 29, 1986, and expired July 29, 2003.
It has no current Paragraph IV, injunction, or Orange Book blocking effect.
Tretinoin is a small molecule, so biosimilar analysis is inapplicable.
Current freedom-to-operate risk, if any, must come from separate formulation, manufacturing, labeling, or unexpired product patents.
Generic launch after approval is not blocked by Patent 4,603,146.

FAQs

Can a company market tretinoin for wrinkles without infringing U.S. Patent 4,603,146?

Yes. The patent expired July 29, 2003. Marketing conduct after expiration cannot infringe the expired patent, although other unexpired patents may remain relevant.

Does Patent 4,603,146 cover retinol or retinaldehyde?

The claim recites vitamin A acid, not retinol or retinaldehyde. Those compounds are chemically distinct from tretinoin and would not ordinarily fall within the claim’s active-ingredient limitation.

Does the patent cover tretinoin gel?

Not automatically. A gel would need to satisfy the “emollient vehicle” limitation and the other claim requirements. In any event, the patent is expired.

Could a new low-irritation tretinoin formulation receive patent protection?

Potentially, if the formulation satisfies patentability requirements and claims a novel, non-obvious composition, delivery system, manufacturing process, or therapeutic result. The expired patent would be prior art but would not itself prevent patenting every later formulation.

Is a cosmetic anti-aging tretinoin product subject to the same FDA pathway as prescription tretinoin?

No. Tretinoin is an FDA-approved prescription drug for specified uses. A product making drug claims, including claims to treat or reverse photoaging-related pathology, may be regulated as a drug rather than solely as a cosmetic.[3,5]

References

United States Patent and Trademark Office. (1986). U.S. Patent No. 4,603,146.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	5289686	⤷ Start Trial
Australia	598454	⤷ Start Trial
Australia	599135	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,603,146

Summary for Patent: 4,603,146